Review Article: New Receptor Targets for Medical Therapy in Irritable Bowel Syndrome

Overview

Journal Aliment Pharmacol Ther

Specialties Gastroenterology
Pharmacology

Date 2009 Sep 30

PMID 19785622

Citations 28

Authors

M Camilleri

Affiliations

Soon will be listed here.

Abstract

Background: Despite setbacks to the approval of new medications for the treatment of irritable bowel syndrome, interim guidelines on endpoints for irritable bowel syndrome (IBS) trials have enhanced interest as new targets for medical therapy are proposed based on novel mechanisms or chemical entities.

Aims: To review the approved lubiprostone, two targets that are not meeting expectations (tachykinins and corticotrophin-releasing hormone), the efficacy and safety of new 5-HT(4) agonists, intestinal secretagogues (chloride channel activators, and guanylate cyclase-C agonists), bile acid modulation, anti-inflammatory agents and visceral analgesics.

Methods: Review of selected articles based on PubMed search and clinically relevant information on mechanism of action, safety, pharmacodynamics and efficacy.

Results: The spectrum of peripheral targets of medical therapy addresses chiefly the bowel dysfunction of IBS and these effects are associated with pain relief. The pivotal mechanisms responsible for the abdominal pain or visceral sensation in IBS are unknown. The new 5-HT(4) agonists are more specific than older agents and show cardiovascular safety to date. Secretory agents have high specificity, low bioavailability and high efficacy. The potential risks of agents 'borrowed' from other indications (such as hyperlipidaemia, inflammatory bowel disease or somatic pain) deserve further study.

Conclusions: There is reason for optimism in medical treatment of IBS with a spectrum of agents to treat bowel dysfunction. However, visceral analgesic treatments are still suboptimal.

Citing Articles

Managing gastrointestinal manifestations in systemic sclerosis, a mechanistic approach.

Kaniecki T, Hughes M, McMahan Z Expert Rev Clin Immunol. 2024; 20(6):603-622.

PMID: 38406978 PMC: 11098704. DOI: 10.1080/1744666X.2024.2320205.

A Mendelian randomization study on the effects of plasma lipids on irritable bowel syndrome and functional dyspepsia.

Xu M, Liu D, Tan Y, He J, Zhou B Sci Rep. 2024; 14(1):78.

PMID: 38167458 PMC: 10761668. DOI: 10.1038/s41598-023-50459-9.

Gut-brain Axis and migraine headache: a comprehensive review.

Arzani M, Jahromi S, Ghorbani Z, Vahabizad F, Martelletti P, Ghaemi A J Headache Pain. 2020; 21(1):15.

PMID: 32054443 PMC: 7020496. DOI: 10.1186/s10194-020-1078-9.

Medical Therapies in the Pipeline for Irritable Bowel Syndrome.

Camilleri M Gastroenterol Hepatol (N Y). 2017; 13(9):550-552.

PMID: 29038646 PMC: 5635431.

Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments.

McQuade R, Stojanovska V, Abalo R, Bornstein J, Nurgali K Front Pharmacol. 2016; 7:414.

PMID: 27857691 PMC: 5093116. DOI: 10.3389/fphar.2016.00414.

References

Cuppoletti J, Malinowska D, Tewari K, Li Q, Sherry A, Patchen M . SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol. 2004; 287(5):C1173-83. DOI: 10.1152/ajpcell.00528.2003. View

Chial H, Camilleri M, Ferber I, Delgado-Aros S, Burton D, McKinzie S . Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol. 2004; 1(3):211-8. DOI: 10.1053/jcgh.2003.50031. View

Fernandez-Banares F, Esteve M, Salas A, Alsina M, Farre C, Gonzalez C . Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics. Am J Gastroenterol. 2007; 102(11):2520-8. DOI: 10.1111/j.1572-0241.2007.01438.x. View

Tayama J, Sagami Y, Shimada Y, Hongo M, Fukudo S . Effect of alpha-helical CRH on quantitative electroencephalogram in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2007; 19(6):471-83. DOI: 10.1111/j.1365-2982.2007.00903.x. View

Tack J, Van Outryve M, Beyens G, Kerstens R, Vandeplassche L . Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2008; 58(3):357-65. DOI: 10.1136/gut.2008.162404. View

Camilleri M, Bharucha A, Ueno R, Burton D, Thomforde G, Baxter K . Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2006; 290(5):G942-7. DOI: 10.1152/ajpgi.00264.2005. View

Grunberg S, Rolski J, Strausz J, Aziz Z, Lane S, Russo M . Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind,.... Lancet Oncol. 2009; 10(6):549-58. DOI: 10.1016/S1470-2045(09)70109-3. View

De Maeyer J, Lefebvre R, Schuurkes J . 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008; 20(2):99-112. DOI: 10.1111/j.1365-2982.2007.01059.x. View

Beattie D, Armstrong S, Shaw J, Marquess D, Sandlund C, Smith J . The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008; 378(1):139-47. DOI: 10.1007/s00210-008-0281-z. View

10.

Houghton L, Fell C, Whorwell P, Jones I, Sudworth D, Gale J . Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut. 2007; 56(9):1218-25. PMC: 1954959. DOI: 10.1136/gut.2006.110858. View

11.

Bouras E, Camilleri M, Burton D, Thomforde G, McKinzie S, Zinsmeister A . Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001; 120(2):354-60. DOI: 10.1053/gast.2001.21166. View

12.

Bassil A, Borman R, Jarvie E, McArthur-Wilson R, Thangiah R, Sung E . Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol. 2008; 154(1):126-35. PMC: 2438971. DOI: 10.1038/bjp.2008.84. View

13.

Delgado-Aros S, Chial H, Camilleri M, Szarka L, Weber F, Jacob J . Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol. 2003; 284(4):G558-66. DOI: 10.1152/ajpgi.00360.2002. View

14.

Bampton P, Dinning P, Kennedy M, Lubowski D, Cook I . The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol Gastrointest Liver Physiol. 2002; 282(3):G443-9. DOI: 10.1152/ajpgi.00194.2001. View

15.

Morganroth J, Brozovich F, McDonald J, Jacobs R . Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol. 1991; 67(8):774-6. DOI: 10.1016/0002-9149(91)90541-r. View

16.

Sinha L, Liston R, Testa H, Moriarty K . Idiopathic bile acid malabsorption: qualitative and quantitative clinical features and response to cholestyramine. Aliment Pharmacol Ther. 1998; 12(9):839-44. DOI: 10.1046/j.1365-2036.1998.00388.x. View

17.

Barrett K, Keely S . Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu Rev Physiol. 2000; 62:535-72. DOI: 10.1146/annurev.physiol.62.1.535. View

18.

Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell G, Santini D . Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004; 126(3):693-702. DOI: 10.1053/j.gastro.2003.11.055. View

19.

Camilleri M, Nadeau A, Tremaine W, Lamsam J, Burton D, Odunsi S . Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol Motil. 2009; 21(7):734-e43. PMC: 2705747. DOI: 10.1111/j.1365-2982.2009.01288.x. View

20.

Corinaldesi R, Stanghellini V, Cremon C, Gargano L, Cogliandro R, De Giorgio R . Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther. 2009; 30(3):245-52. DOI: 10.1111/j.1365-2036.2009.04041.x. View